A Phase 3 interventional study of Standard Conventional Radiotherapy and Stereotactic Body Radiotherapy in Cancer Metastatic, sponsored by Canadian Cancer Trials Group. Recruiting at 13 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Canadian Cancer Trials Group · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 353 studies in Neoplasm Metastasis with a site in Canada — 58 open to participants now, 116 under way, 39 of them phase 3. Neoplasm Metastasis · Canada.
Among the 353 studies in Neoplasm Metastasis with a site in Canada, this one is the 132nd largest by planned enrollment of the 323 interventional ones that give a count, is one of 21 that started in 2025, is one of 98 in phase 3, reaches primary completion later than 60 of the 115 other live ones, and was the 318th registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →58 of the 353 studies in Neoplasm Metastasis with a site in Canada are open now. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
Amgen · Sites in Canada, United States, Australia and 7 more countries
Ages 18–99
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
Ipsen · Sites in Canada, United States, France and 1 more country
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
353 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 94 · Phase 2 126 · Phase 3 108 · Phase 4 4
First in 1994; this study’s year is marked. 21 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 230 is above the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 152 across the 323 interventional studies, 80 across the 25 observational. Of the 221 that completed or were terminated, 105 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
218 of 353 have an industry lead sponsor. The 10 most frequent:
Canadian Cancer Trials Group is the lead sponsor of 93 studies on the registry; 29 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Canadian Cancer Trials Group has 3 studies filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
31 of the studies in Neoplasm Metastasis with a site in Canada that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT06391242Phase 3Canadian Cancer Trials GroupStereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases | 2027-07-01 |
| NCT06103864Phase 3AstraZenecaA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | 2027-07-28 |
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
Add all 31 to your calendar (.ics) → With an account.
Among the 353 studies in Neoplasm Metastasis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to answer the following question: Is Stereotactic Body Radiation Therapy or SBRT (a form of radiation therapy which can deliver high doses of radiation to the specific painful area of the body most affected by cancer, while keeping the radiation beams away from the healthy parts of the body that surround the cancer) better for pain relief than the standard treatment of conventional radiation therapy or CRT (a form of radiation therapy which delivers radiation to the painful area but can also negatively affect other parts of the body in the same area)
This is a multi-centre, phase III randomized controlled trial comparing SBRT to conventional palliative EBRT in patients with solid tumours and a dominant painful non-spine bone metastasis as defined by a worst pain score of 2 or greater. 230 participants will be enrolled to the study. Participants will have radiation for 5 treatments (conventional palliative EBRT 20Gy/5; SBRT 30Gy/5 or 35Gy/5) and then will be followed for pain response and radiological progression at 3 and 6 months post treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiation: Standard Conventional Radiotherapy
Radiation: Stereotactic Body Radiotherapy
20Gy in 5 fractions
30 or 35Gy in 5 fractions
Complete pain response utilizing the Cochran-Mantel-Hanzeal test
Time frame: 27 months
Pain response pattern at 3 months: partial, stable or progressive pain
Time frame: 27 months
Early (1 month post RT) and late (6 months post RT) CPR and response patterns (partial, stable, and progressive pain);
Time frame: 27 months
Re-irradiation rate within the 6-month follow-up period
Time frame: 27 months
Incidence of fracture at the radiation target site
Time frame: 27 months
Incidence of treatment-related AE rates >/- grade 2 utilizing CTCAE v5
Time frame: 27 months
Imaging-based local control rates at 3 and 6 months post-treatment
Time frame: 27 months
Patient reported outcomes utilizing EORTC QLQ-C30
Time frame: 27 months
Patient reported outcomes utilizing EORTC QLQ-BM22
Time frame: 27 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Jul 2027, 27 months after the start.
Of 55 non-industry phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 108. This study's planned 27 months is below that.
Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Canadian Cancer Trials Group